The biotechnology, pharmaceutical and medical device sectors are witnessing significant activity on public and private capital markets. Hong Kong is an active venue, with 36 life science companies, predominantly from mainland China, filing for IPOs in H1 2025. The U.K. is pursuing a strategic initiative to reduce drug approval costs by 25%, aiming to stimulate innovation and attract investment. Additionally, various biopharma and med-tech incubators in Australia received nearly AU$100 million in grants to bolster startup ecosystems. Meanwhile, med-tech firms continue to raise capital via public offerings and private financings in the U.S.